Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Mielke

Showing results (51-60 of 126) with videos related to

Pageof 13
Sort By:
Transplantation and Cellular Therapy|October 10, 2023
Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationGiorgia Battipaglia, Myriam Labopin, Stephan Mielke, et al.
Bone Marrow Transplantation|October 6, 2020
Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemiaAli Bazarbachi, Myriam Labopin, Didier Blaise, et al.
Leukemia|August 21, 2019
Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMTNoga Shem-Tov, Christophe Peczynski, Myriam Labopin, et al.
Blood|December 21, 2022
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM studyJeremy S Abramson, Scott R Solomon, Jon Arnason, et al.
Leukemia|March 28, 2024
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?Olaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Transplantation and Cellular Therapy|July 28, 2024
Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMTSebastian Giebel, Myriam Labopin, Zinaida Peric, et al.
Bone Marrow Transplantation|March 6, 2026
Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working PartyGesine Bug, Myriam Labopin, Jennifer L Byrne, et al.
Diagnostics (Basel, Switzerland)|March 6, 2021
Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell TransplantationEva Wagner-Drouet, Daniel Teschner, Christine Wolschke, et al.
Bone Marrow Transplantation|September 22, 2022
Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)Eleni Gavriilaki, Myriam Labopin, Ioanna Sakellari, et al.
Bone Marrow Transplantation|April 13, 2024
Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Myriam Labopin, Ryszard Swoboda, et al.
Pageof 13

Showing results (51-60 of 126) with videos related to

Sort By:
Pageof 13
Transplantation and Cellular Therapy|October 10, 2023
Thiotepa-Based Regimens Are Valid Alternatives to Total Body Irradiation-Based Reduced-Intensity Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationGiorgia Battipaglia, Myriam Labopin, Stephan Mielke, et al.
Bone Marrow Transplantation|October 6, 2020
Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemiaAli Bazarbachi, Myriam Labopin, Didier Blaise, et al.
Leukemia|August 21, 2019
Haploidentical vs. unrelated allogeneic stem cell transplantation for acute lymphoblastic leukemia in first complete remission: on behalf of the ALWP of the EBMTNoga Shem-Tov, Christophe Peczynski, Myriam Labopin, et al.
Blood|December 21, 2022
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM studyJeremy S Abramson, Scott R Solomon, Jon Arnason, et al.
Leukemia|March 28, 2024
ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?Olaf Penack, Mouad Abouqateb, Christophe Peczynski, et al.
Transplantation and Cellular Therapy|July 28, 2024
Impact of the Type of Tyrosine Kinase Inhibitor (imatinib or dasatinib) Used Before allo-HCT on Outcome of Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia. A Study on Behalf of the Acute Leukemia Working Party of the EBMTSebastian Giebel, Myriam Labopin, Zinaida Peric, et al.
Bone Marrow Transplantation|March 6, 2026
Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working PartyGesine Bug, Myriam Labopin, Jennifer L Byrne, et al.
Diagnostics (Basel, Switzerland)|March 6, 2021
Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell TransplantationEva Wagner-Drouet, Daniel Teschner, Christine Wolschke, et al.
Bone Marrow Transplantation|September 22, 2022
Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia Working Party (ALWP)Eleni Gavriilaki, Myriam Labopin, Ioanna Sakellari, et al.
Bone Marrow Transplantation|April 13, 2024
Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host disease prophylaxis post allogeneic stem cell transplantation from sibling and unrelated donors in patients with acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationArnon Nagler, Myriam Labopin, Ryszard Swoboda, et al.
Pageof 13